Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (275)	11/26/1998 10:08:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 656

Immunex Corp. Reiterated 'Buy' at Adams, Harkness Bloomberg News November 25, 1998, 4:03 p.m. ET Princeton, New Jersey, Nov. 25 (Bloomberg Data) -- Immunex Corp. (IMNX US) was reiterated ''buy'' by analyst Carol Werther at Adams, Harkness & Hill. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652

To: Anthony Wong who wrote (275)	11/26/1998 4:29:00 PM
From: Platter	Read Replies (1) \| Respond to of 656

Recent Reuters article excerpt - "Company spokesman Tim Warner said Immunex was unaware of any reason behind the spike in the company's stock price but said Wall Street was buzzing with excitement about its latest drug Enbrel, recently launched for the treatment of arthritis. But several analysts said the stock's sudden rise may have more to do with investors' speculation in biotech stocks which have performed well recently despite a choppy stock market. ''I think there is just rampant speculative investment in the biotech group at the moment,'' said Matthew Geller, an analyst at CIBC Oppenheimer. ''Investors are just playing sectors, there is no rationale for it, it's irrational throwing money at stocks and Immunex is one of those hot stocks...and it's a good way to lose,'' Geller said."